Aqr Capital Management LLC Cullinan Oncology, Inc. Transaction History

Aqr Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$9.05 - $11.72 $452,934 - $586,562	-50,048 Reduced 69.68%	21,774 $197,000
Q2 2023 Aug 14, 2023	SELL	$8.8 - $13.4 $144,936 - $220,698	-16,470 Reduced 18.65%	71,822 $772,000
Q1 2023 May 15, 2023	SELL	$10.2 - $11.91 $235,293 - $274,739	-23,068 Reduced 20.71%	88,292 $903,000
Q4 2022 Feb 14, 2023	BUY	$9.72 - $13.62 $28,751 - $40,287	2,958 Added 2.73%	111,360 $1.17 Million
Q3 2022 Nov 14, 2022	BUY	$11.82 - $15.42 $1.03 Million - $1.35 Million	87,493 Added 418.45%	108,402 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $13.55 $152,844 - $283,316	20,909 New	20,909 $268,000

146

67.6M

612K

118K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $499M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.